Camoteskimab

Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular disorders and autoinflammatory disorders, including adult-onset Still’s disorder (AOSD) and multiple myeloma[1][2][3][4][5].